

2026 FARE Clinical Development Day

Beyond One-Size-Fits-All

Translating Food Allergy Heterogeneity into Better Trials and Care

October 29, 2026

The Dupont Circle Hotel

Washington, D.C.

FARE

Food Allergy Research & Education

A Letter from the CEO



Welcome to FARE's 2026 Clinical Development Day. I am grateful that you have chosen to join us for what has become one of FARE's most important opportunities to bring the food allergy field together.

This year's theme, "Beyond One-Size-Fits-All: Translating Food Allergy Heterogeneity into Better Trials and Care," reflects both how far our field has come and the challenge now before us. We increasingly understand that food allergy is not a single, uniform disease. Biology, reaction thresholds, natural history, treatment response, patient experience, access to care, and many other factors differ substantially from one person to another. Our research, clinical trials, treatments, and care models must account for that complexity.

Clinical Development Day was created because progress requires more than excellent science conducted in parallel. It requires the people who generate evidence, develop therapies, regulate products, deliver care, fund research, and represent the needs of the food allergy community to be in conversation with one another. Today, we have brought those perspectives together with a deliberate goal—to learn from one another, challenge assumptions, identify shared priorities, and determine where collective action can accelerate progress.

Our morning discussions will examine some of the most consequential questions facing the field: how variability across demographics and reaction thresholds should influence research and care; how we can better measure outcomes that matter to patients; and how we can design research, clinical trials, and treatment pathways that are both scientifically rigorous and equitable.

The afternoon has been designed to harness the extraordinary expertise in this room. Together, we will identify priorities across the food allergy ecosystem, hear perspectives from leaders spanning research, clinical practice, government, and therapeutic development, and then work in smaller groups to explore what those priorities mean for the field. We have also intentionally created space for the conversations that often prove most valuable at scientific meetings—the conversations between people who may approach the same problem from very different vantage points but discover that they have something important to build together.


FARE has long believed that convening is itself a catalyst for progress. Clinical Development Day is not intended to end when the final session concludes. The ideas, connections, areas of consensus—and even the areas where we disagree—should help inform what comes next for our field.

So, I encourage you to participate fully today. Ask difficult questions. Share what you know, but also what you do not know. Seek out someone whose expertise or perspective differs from your own. And when you see an opportunity for collaboration, do not let it remain simply an interesting conversation.

The food allergy community is counting on all of us to turn scientific progress into meaningful change: better ways to prevent disease, more precise diagnostics, safer and less burdensome treatments, more equitable access to care, and ultimately therapies that can fundamentally alter the course of food allergy. The breadth of priorities before us underscores why no single institution, sector, or discipline can accomplish this alone.

Thank you for bringing your expertise, your curiosity, and your willingness to collaborate. I look forward to seeing what we can accomplish together.

Warmly,



Sung Poblete, PhD, RN

Chief Executive Officer

FARE (Food Allergy Research & Education)

Agenda for Thursday, October 29, 2026

Beyond One-Size-Fits-All: Translating Food Allergy Heterogeneity into Better Trials and Care

Food allergy is increasingly recognized not as a single disease, but as a spectrum of complex and heterogeneous conditions shaped by diverse biological mechanisms, environmental influences, demographics, and lived experiences. As the field advances toward precision medicine, there is growing urgency to better understand why patients experience food allergy differently—and how those differences should inform diagnosis, treatment, clinical trial design, and long-term management.

"Beyond One-Size-Fits-All: Translating Food Allergy Heterogeneity into Better Trials and Care" will convene leading researchers, clinicians, industry innovators, patient advocates, and regulators to explore the evolving science and real-world implications of disease heterogeneity. Through multidisciplinary discussion and collaboration, the conference will examine how variability across populations, immune endotypes, symptom severity, treatment response, and social determinants of health can shape more personalized and equitable approaches to care.

Sessions will explore variability across food allergy phenotypes, the integration of patient-reported outcomes into research and care models, and strategies to improve equity and representation in clinical trials. Additional discussions will focus on translating emerging precision medicine insights into clinical practice and addressing disparities in access to diagnostics, treatments, and specialty care.

By bringing together diverse perspectives across the food allergy community, this conference aims to challenge traditional one-size-fits-all approaches and catalyze a future in which food allergy diagnosis, treatment, and management are more precise, inclusive, and responsive to the needs of every patient.

Morning Sessions

7:15 AM – 8:00 AM **Breakfast & Networking**

8:00 AM – 8:10 AM **Welcome & Opening Remarks**

- Sung Poblete, PhD, RN, CEO of FARE
- Sarita Patil, MD, Harvard Medical School, Mass General Brigham
- Stephen Tilles, MD, FARE and University of Washington
- Yamini Virkud, MD, MA, MPH, University of North Carolina at Chapel Hill

8:10 AM – 9:10 AM **Variability Across Demographics and Thresholds**

Food allergy does not affect all individuals equally. Reaction severity, allergen thresholds, natural history, and treatment response vary significantly, yet much of the current evidence base and many clinical approaches continue to rely on generalized assumptions that may overlook important differences among patient populations.

This session will explore the biological, clinical, and social factors that contribute to variability in food allergy presentation and outcomes across diverse populations. Sessions will examine differences in reaction thresholds, disease persistence, comorbidities, and risk profiles, as well as emerging research on how genetics, environment, diet, microbiome composition, and social determinants of health may shape disease expression. Discussions will also address challenges in defining clinically meaningful thresholds and the implications of demographic variability for diagnosis, risk assessment, food labeling, and treatment strategies.

By deepening understanding of heterogeneity across populations, this session aims to advance more personalized, evidence-based, and equitable approaches to food allergy research and care.

Presenter: Scott Sicherer, MD, Icahn School of Medicine at Mount Sinai

Panelists:

- Mary Grace Baker, MD, MS, Icahn School of Medicine at Mount Sinai
- Pamela Frischmeyer-Guerrerio, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Wayne Shreffler, MD, PhD, Harvard Medical School; Mass General Brigham

Moderator: Sarita Patil, MD

9:10 AM – 10:10 AM **Patient-Reported and Patient-Centered Outcomes**

Food allergy affects far more than the risk of an allergic reaction. It shapes daily decisions, emotional wellbeing, social participation, family life, and quality of life. Yet clinical trial endpoints, such as oral food challenge results, often miss the concerns that matter most to patients and caregivers, including anxiety, uncertainty, dietary restrictions, and treatment burden.

As new diagnostics and therapies emerge, researchers need ways to assess whether they improve everyday life as well as clinical outcomes. Patient-reported measures offer valuable insight, but many have not been adequately validated to measure treatment response or established as endpoints for regulatory decisions.

This session will examine how patient-reported outcomes and the broader set of patient-centered outcomes can guide food allergy research, therapeutic development, and clinical care. Discussions will consider how priorities and experiences vary across ages, cultures, and disease phenotypes, and how to measure changes in confidence, social participation, and the burden of managing risk.

Presenter: Brian Vickery, MD, Emory University School of Medicine

Panelists:

- Jennifer Dantzer, MD, MHS, Johns Hopkins University School of Medicine
- Todd Green, MD, DBV Technologies, University of Pittsburgh School of Medicine
- Adora Lin, MD, PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Anubha Tripathi, MD, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Moderator: Stephen Tilles, MD

10:10 AM – 10:25 **Break**

10:25 AM – 11:55 AM **Equity in Research and Care**

Advancing food allergy research requires studies that reflect the full patient population, including historically underrepresented groups and those with rare or less well-characterized disease endotypes. Equity must extend beyond FDA approval to ensure timely, affordable access and the clinical capacity to deliver safe, sustained treatment.

This session will explore barriers and solutions across research and routine care, including inclusive recruitment, community trust, and study designs that capture diverse patient experiences and endotypes. Adaptive trials, decentralized and hybrid models, and real-world evidence offer opportunities to broaden participation and better understand treatment outcomes.

Discussions will also address coverage, affordability, referral pathways, clinician education, shared decision-making, and practice capacity. Participants will consider how implementation planning, community-based care, patient support, and cross-sector coordination can help translate rigorous, inclusive research into therapies that benefit patients across the spectrum of food allergy.

Presenter: Carla Davis, MD, Howard University College of Medicine

Panel 1: Designing Trials That Reflect the Unmet Need

- Amaziah Coleman, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Megan Dean, PhD, MA, Michigan State University
- Edith Perez, MD, Cornerstone Specialty Network
- Julie Wang, MD, Icahn School of Medicine at Mount Sinai

Panel 2: From Approval to Access—Ethical Considerations in Food Allergy Treatment

- Vivian Hernandez-Trujillo, MD, Florida International University
- Punita Ponda, MD, Albert Einstein College of Medicine
- Sherry Zhou, MD, MSc, ALK-Abelló

Moderator: Yamini Virkud, MD, MA, MPH

11:55 AM – 12:05 PM **Audience Poll**

Afternoon Sessions

12:05 PM – 1:25 PM **Group Photo, Lunch, and Networking**

1:25 PM – 2:20 PM **Responding to the Field: Expert Perspectives**

Building on insights from the morning sessions and the audience poll, experts will identify priorities for advancing the food allergy field and discuss the actions needed to turn them into progress.

Panelists:

- Daniel Adelman, MD, University of California, San Francisco
- Carla Davis, MD, Howard University College of Medicine
- David Fitzhugh, MD, Allergy Partners of Chapel Hill
- Ronald Rabin, MD, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
- Kelly Stone, MD, PhD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- Alkis Togias, MD, National Institute of Allergy and Infectious Diseases, National Institutes of Health

Moderator: Stephen Tilles, MD

Facilitators: Sarita Patil, MD and Yamini Virkud, MD, MA, MPH

2:20 PM – 3:20 PM **Conversations that Move the Field**

In small, mixed-stakeholder groups, participants will draw on the audience poll and expert panel perspectives to identify priorities and practical next steps for the food allergy field. Each group will document its conclusions, and a designated note-taker will share a brief report with the full assembly to surface common themes and areas of agreement.

Moderator: Lee Gimpel

3:20 PM – 3:35 PM **Break**

3:35 PM – 4:15 PM **The Day in Perspective: Key Takeaways and Paths Forward**

In this culminating session, participants will identify the single issue that matters most to them in their work or connection to the food allergy field—and the actions they want to see next. FARE leadership and the meeting co-chairs will connect these priorities to concrete next steps and explain how the day's insights may guide future work.

Moderator: Lee Gimpel

Facilitators: Sarita Patil, MD, Yamini Virkud, MD, MA, MPH and Stephen Tilles, MD

4:15 PM – 4:30 PM **Closing Remarks & Adjourn**

Moderators: Lee Gimpel, Sarita Patil, MD, Yamini Virkud, MD, MA, MPH and Stephen Tilles, MD

4:30 PM onward **Afterglow**

Local attendees or those with late or next day departures are welcome to gather in the hotel bar to continue conversations, deepen relationships, and process the day's discussions after the formal program concludes.



Biographies of Speakers

Daniel Adelman, MD



University of California, San Francisco

Dr. Adelman holds an academic appointment at the University of California, San Francisco as adjunct professor of medicine, and is a fellow of the American Academy of Allergy, Asthma, and Immunology, the Clinical Immunology Society, and the American College of Physicians.

For over 30 years, Dr. Adelman has been developing novel therapeutics in the biotechnology industry in the San Francisco Bay Area. Dr. Adelman was chief medical officer at Aimmune Therapeutics where he was responsible for leading the development of Palforzia®, the first treatment for patients with food allergies approved by the U.S. Food and Drug Administration and the European Medicines Agency. Prior to that he was senior vice president of development and chief medical officer at Alvine Pharmaceuticals Inc., a biotechnology company devoted to the development of pharmaceutical treatment for celiac disease. Earlier in his career, Dr. Adelman was senior vice president of development and chief medical officer at Sunesis Pharmaceuticals, served in various roles at Pharmacyclics, including VP of Clinical Operations and Biometrics, and was a Clinical Scientist at Genentech where he led the early clinical development of two therapeutic monoclonal antibodies, Xolair® and Avastin®. Dr. Adelman has been involved in all stages of pharmaceutical drug development and is extensively published.

Dr. Adelman trained in internal medicine and was a clinical and research fellow at University of California, Los Angeles in the Division of Clinical Immunology and Allergy. He then completed a National Institutes of Health/Public Health Service Tumor Immunology Fellowship. Dr. Adelman then took a position on the faculty at University of California, San Francisco, School of Medicine, where he was director of Clinical Allergy/Immunology in the Division of Allergy and Immunology, and director of the Outpatient Center for Clinical Research. He holds an AB degree in biology from University of California, Berkeley and received his medical degree from the University of California, Davis.

Mary Grace Baker, MD, MS



Icahn School of Medicine at Mount Sinai

Dr. Baker is an associate professor of Pediatrics at the Icahn School of Medicine at Mount Sinai (ISMMS). Her clinical practice is devoted to caring for children with food allergy, and she has a special interest in food protein-induced enterocolitis syndrome (FPIES). She is an investigator on several clinical trials to advance our ability to diagnose and treat food allergy, including the first NIH-funded study to learn more about the immunology underlying FPIES and how best to conduct food challenges for this condition.

Her work connects clinical care with research aimed at improving food allergy diagnosis and treatment. Through her focus on FPIES, she contributes to efforts to better understand this condition and inform how oral food challenges are conducted.

Dr. Baker earned her medical degree from the University of Virginia, completed her residency in internal medicine at Yale New Haven Hospital, and then pursued her fellowship in allergy and immunology at ISMMS. She also completed a master's degree in clinical research at ISMMS.

Biographies of Speakers

Amaziah Coleman, MD



National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Dr. Coleman has served as a medical officer/physician in the Allergy, Asthma and Airway Biology Branch (AAABB) within the Division of Allergy, Immunology and Transplantation (DAIT) at the NIAID since 2021. She leads studies in the Childhood Asthma in Urban Settings (CAUSE) consortium, the Atopic Dermatitis Research Network (ADRN) and the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). She additionally leads investigator-initiated and small-business clinical trials focused on food allergy diagnosis and management. Dr. Coleman has conducted original research in pediatric asthma and food allergy and has expertise in health equity leadership and improving representation in clinical research studies. She leads the community engagement initiatives within the Allergy, Asthma and Airway Biology Branch at NIAID.

Dr. Coleman received her medical degree from the University of Mississippi Medical Center. She completed a pediatric residency at the University of Arkansas/Arkansas Children's Hospital and a postdoctoral fellowship in allergy and immunology at the University of Wisconsin School of Medicine and Public Health.

Jennifer Dantzer, MD, MHS



Johns Hopkins University School of Medicine

Dr. Dantzer is an associate professor of pediatrics at Johns Hopkins University School of Medicine in the Division of Allergy, Immunology, and Rheumatology. Her research is focused on food allergy treatments and patient-centered outcomes with a specific interest in understanding patients' perspectives and preferences. In 2021, she was awarded the Johns Hopkins Clinical Scholar Award and then transitioned to a National Institutes of Health-funded K23 award to study patient-centered outcomes of the first monoclonal antibody approved for food allergy by the U.S. Food and Drug Administration. She was recently awarded a FARE Mid-Career Investigator Award.

Dr. Dantzer is also a co-investigator in the Consortium for Food Allergy Research and participates in numerous other food allergy research projects. She has published articles in leading allergy and immunology journals, including recent articles on the OUtMATCH Study and IMPACT study follow-up, as well as review articles on novel treatments for food allergy.

Dr. Dantzer received her bachelor's degree in biology and psychology and then earned her medical degree from the University of Louisville. She completed her pediatric residency at the Children's Hospital of Pittsburgh and her fellowship in allergy and immunology at Johns Hopkins. She then completed a Master of Health Science at the Johns Hopkins Bloomberg School of Public Health.

Carla Davis, MD



Howard University College of Medicine

Dr. Davis is professor of pediatrics and chair of the Department of Pediatrics and Child Health at the Howard University College of Medicine. Previously, Dr. Davis was chief of the Immunology, Allergy, and Retrovirology Division in the Baylor College of Medicine (BCM) Department of Pediatrics where she founded and served as director of the federally-funded Texas Children's Hospital Food Allergy Program from 2015–2024. Dr. Davis currently serves as the President of the American Academy of Allergy, Asthma, and Immunology.

Dr. Davis focuses on improving the quality of life for children with allergic and immunologic diseases, most specifically food allergy and asthma, and has participated as a site principal investigator in multiple NIH-funded clinical trials. She has more than 20 years of experience in leading translational, educational and clinical research efforts, with over 145 publications. She leads community initiatives to address medical and food insecurity in underserved populations to mitigate health disparities. Dr. Davis has special expertise in food allergies, eosinophilic gastrointestinal disease, and asthma. She leads a translational laboratory to discover underlying molecular pathophysiologic mechanisms in allergic diseases.

Dr. Davis received her bachelor's degree in chemical engineering from Howard University and her medical degree from Duke University. She completed her allergy and immunology fellowship at BCM.

Megan Dean, PhD, MA



Michigan State University

Dr. Dean is Assistant Professor of Philosophy at Michigan State University (MSU). She works in feminist bioethics with a focus on the ethics of food and eating. Her research explores the ethical complexity of eating and its implications for clinical ethics, diet research, personal food choice, and eating with and feeding others. Recent projects focus on the ethics of eating with and feeding those who eat differently from ourselves, including those with food allergy. Dr. Dean also serves as the North American Coordinator for Culinary Mind: Center for the Philosophy of Food.

Dr. Dean earned a Bachelor of Arts (Honours) in Philosophy and Contemporary Studies from the University of King's College, in Canada, a Master of Arts in Philosophy from the University of Alberta, and a PhD in Philosophy from Georgetown University. Before joining the faculty at MSU, she was the Chauncey Truax Postdoctoral Fellow and Visiting Assistant Professor of Philosophy at Hamilton College in New York.

Biographies of Speakers

David Fitzhugh, MD




Allergy Partners of Chapel Hill

Dr. Fitzhugh has been a private practice allergist for decades and is currently a physician partner at Allergy Partners of Chapel Hill. His clinical work focuses primarily on the diagnosis and treatment of food allergy. As a community-based allergist, his mission is to broaden the availability of food immunotherapy, while still striving to contribute to the knowledge base of the food allergy field. He is the past chairperson of Allergy Partners' internal food allergy committee and has been responsible for standardizing the delivery protocols for both OIT (oral immunotherapy) and food SLIT (sublingual immunotherapy) across the practice. He is a frequent speaker at the FAST (Food Allergy Support Team) annual conference.

Dr. Fitzhugh earned a bachelor's degree in biochemistry with honors at Cornell University and his medical degree from Virginia Commonwealth University. He completed his clinical training with an internal medicine residency at the University of North Carolina at Chapel Hill, followed by an allergy and immunology fellowship at the University of South Florida.

Pamela Frischmeyer-Guerrerio, MD, PhD



National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Dr. Frischmeyer-Guerrerio is chief of the Laboratory of Allergic Diseases and chief of the Food Allergy Research Section at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), where she also serves as a senior investigator. A physician-scientist and pediatric allergist-immunologist, Dr. Frischmeyer-Guerrerio leads a research program focused on understanding the genetic, immunologic, and biochemical mechanisms underlying food allergy, eosinophilic esophagitis, and related allergic conditions.

Dr. Frischmeyer-Guerrerio's research integrates basic, translational, and clinical investigation to identify factors influencing the development, severity, and persistence of food allergy. Her work includes investigating genetic disorders associated with allergic disease, characterizing immune pathways involved in allergic sensitization and tolerance, and identifying biomarkers and novel strategies for food allergy prevention and treatment. She joined NIAID in 2014 as chief of the Food Allergy Research Unit, following an academic appointment at Johns Hopkins University. Her contributions to allergy research have been recognized with several honors, including the Presidential Early Career Award for Scientists and Engineers.

Dr. Frischmeyer-Guerrerio earned her bachelor's degree in biology from the University of Iowa and both her medical degree and PhD in human genetics from Johns Hopkins University. She completed her pediatrics residency and allergy and immunology fellowship at Johns Hopkins Hospital.

Lee Gimpel



Better Meetings

Mr. Gimpel is the founder of Better Meetings, a Washington, D.C.-based meeting design, facilitation, and training firm specializing in creating engaging, collaborative, and results-oriented meetings, conferences, and strategic convenings. An experienced facilitator and event strategist, he helps organizations move beyond traditional presentations to foster meaningful dialogue, strengthen connections, and translate shared ideas into actionable outcomes.

Mr. Gimpel has worked with a diverse range of organizations, including the World Bank, Conservation International, Sodexo, and major professional associations, designing and facilitating meetings that encourage active participation and cross-disciplinary collaboration. His approach emphasizes inclusive discussion, creative problem-solving, and innovative meeting formats that draw on the collective expertise of participants.

A frequent speaker and commentator on meeting effectiveness and audience engagement, Mr. Gimpel has contributed to Forbes and been featured in publications including USA Today and The Guardian. He has produced the Conference Organizers Summit, led a global community of practice for meeting facilitators, and serves on the Board of Directors of the Association of Meeting Professionals.

Todd Green, MD



DBV Technologies and University of Pittsburgh School of Medicine

Dr. Green is a pediatric allergist-immunologist, clinical associate professor of pediatrics at the University of Pittsburgh School of Medicine, and vice president of clinical development and medical affairs at DBV Technologies. He maintains an active clinical practice at UPMC Children's Hospital of Pittsburgh while contributing to the advancement of novel food allergy therapies. Dr. Green brings extensive experience spanning patient care, academic research, and therapeutic development, including pioneering work in food allergy oral immunotherapy.

Dr. Green earned his medical degree from the University of Pittsburgh School of Medicine, completed his pediatric residency at The Barbara Bush Children's Hospital at Maine Medical Center, and pursued fellowship training in allergy and immunology at Duke University Medical Center. During his fellowship, he participated in pioneering food allergy oral immunotherapy research under the mentorship of Dr. Wesley Burks. He previously attended Yale University.

Biographies of Speakers

Vivian Hernandez-Trujillo, MD



Florida International University


Dr. Vivian Hernandez-Trujillo is clinical professor of pediatrics at the Herbert Wertheim School of Medicine at Florida International University. She serves as Chief and medical director of the Division of Allergy and Immunology at Nicklaus Children's Hospital, as well as program director of the allergy and immunology fellowship training program. She founded the Allergy and Immunology Care Center of South Florida, which was a longstanding member of the FARE Clinical Network.

Dr. Hernandez-Trujillo is interested in education regarding pediatric food allergy and anaphylaxis. Dr. Hernandez-Trujillo has served as principal investigator or co-principal investigator on a number of clinical studies on primary immunodeficiency, anaphylaxis and food allergy, and has presented abstracts, posters, and lectures at meetings and conferences worldwide. Her most recent research and work has focused on health care disparities.

Her current interests are focused on health care disparities, particularly the impact on Hispanic/Latinx patients. She has also led several efforts to increase early solid food introduction in infants in collaboration with the American Academy of Pediatrics.

Dr. Hernandez-Trujillo received her medical degree from Albany Medical College, New York. She completed a pediatric residency at Miami Children's Hospital followed by an allergy and immunology fellowship at the University of Tennessee, Memphis, St. Jude Children's Research Hospital and Le Bonheur Children's Hospital.

Adora Lin, MD, PhD



National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Dr. Lin is a medical officer in the Division of Allergy, Immunology, and Transplantation (DAIT) in the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), where she oversees clinical trials in food allergy treatment, prevention, and diagnosis. She also cares for patients as a pediatric allergist at Children's National Hospital. Prior to joining DAIT, she was a principal investigator in the Children's National Research Institute, where she studied the regulation of B cells and immunoglobulin production during the development of food allergy and allergic asthma, as well as the role of regulatory B cells in both healthy children and children with allergic diseases.

Dr. Lin earned a bachelor's degree in biology from the Massachusetts Institute of Technology, followed by her doctorate in immunobiology from the University of Cincinnati and her medical degree from the University of Cincinnati College of Medicine. She completed her clinical training with a pediatrics residency at Children's National Hospital, followed by an allergy and immunology fellowship at NIAID.

Sarita Patil, MD
Clinical Development Day Co-chair



Harvard Medical School, Mass General Brigham

Dr. Patil is an associate professor at Harvard Medical School in the Program in Immunology and in the Division of Allergy and Immunology at Mass General Brigham. She serves as co-director of the Food Allergy Center and Multidisciplinary Eosinophilic Gastrointestinal Disease Clinic at Massachusetts General Hospital. She leads a translational research program, including both clinical trials and fundamental research. Her laboratory focuses on understanding allergen-specific antibody and B-cell responses in both the initiation and treatment of allergic diseases. She has led multiple conferences in the field of allergy including the Gordon Research Conference in Food Allergy and the American Academy of Allergy, Asthma, and Immunology (AAAAI) Discovery Meeting.

Dr. Patil earned a bachelor's in human biology with honors from Stanford University and her medical degree from Duke University, which included a Howard Hughes Medical Research Fellowship. She completed her clinical training with an internal medicine residency at the University of Pennsylvania followed by an allergy and immunology fellowship at what was formerly Massachusetts General Hospital.

Edith Perez, MD



Cornerstone Specialty Network

Dr. Perez is chief medical officer of Cornerstone Specialty Network, Professor Emeritus of Medicine at Mayo Clinic, and an internationally recognized physician-scientist and leader in translational research, oncology drug development, and health equity. She serves on the Board of Directors of FARE (Food Allergy Research & Education) and as Co-chair of FARE's Health Equity Advisory Council.

As chief medical officer of Cornerstone Specialty Network, Dr. Perez leads clinical programs and evidence-based initiatives to advance innovation and improve patient outcomes across community oncology practices. She served as chief medical officer at Bolt Biotherapeutics from 2020 to 2024, overseeing clinical development, regulatory affairs, pharmacovigilance, biostatistics, and medical affairs. She also served as vice president and head of U.S. BioOncology Medical Affairs at Genentech, where she helped lead clinical trials and the launch of six oncology therapies.

Dr. Perez spent more than two decades at Mayo Clinic, where she held numerous academic and leadership positions and conducted pioneering research in breast cancer therapeutics and predictive biomarkers. She has authored or co-authored more than 700 peer-reviewed manuscripts and abstracts and has held national leadership roles advancing diversity and representation in clinical research, including initiatives with the American Society of Clinical Oncology, the American Association for Cancer Research, and Stand Up To Cancer.

Dr. Perez earned her bachelor's degree in biology and medical degree from the University of Puerto Rico. She completed her internal medicine residency at Loma Linda University Medical Center and her hematology and oncology fellowship at the University of California, Davis School of Medicine. She also pursued executive education at the Wharton School of the University of Pennsylvania and Harvard Kennedy School.

Biographies of Speakers

Sung Poblete, PhD, RN



FARE (Food Allergy Research & Education)

Dr. Poblete is the chief executive officer of FARE. Prior to joining FARE in 2022, she served as CEO of Stand Up To Cancer (SU2C) for more than a decade. Early in her career, she held executive positions with a focus on patient outcomes and disease management. Notably, as vice president of clinical operations for a subsidiary of Fresenius Medical Care North America, she developed and implemented a national chronic kidney disease management program. As executive director of the Oxford Health Plans Foundation, she facilitated grants that furthered research and programs aimed at improving health care delivery. She currently serves as a member of the Board of Directors for Apricity Health, UbiVac, Proteus, Osteosarcoma Institute, and the Pacific Pediatric Neuro-Oncology Consortium (PNOC), and she is on the advisory board of Nok Nok and Medically Home.

Dr. Poblete has been the recipient of numerous high-level research funding grants from the Centers for Disease Control and Prevention, National Institutes of Health, National Science Foundation, and private foundations. She earned her Bachelor of Science and Master of Science degrees, as well as a doctorate in nursing, from Rutgers, The State University of New Jersey, which honored her with a 2016 induction into the Rutgers Hall of Distinguished Alumni.

Punita Ponda, MD



Albert Einstein College of Medicine

Dr. Ponda is chief of the Division of Allergy and Immunology at the Children's Hospital at Montefiore Einstein and associate professor of Pediatrics and Medicine at Albert Einstein College of Medicine. A board-certified allergist-immunologist, clinician-scientist, and educator, Dr. Ponda has extensive experience in clinical care, research, and medical education, with particular expertise in food allergy, eosinophilic gastrointestinal diseases, and allergen immunotherapy.

Dr. Ponda's research focuses on the mechanisms underlying allergic disease, including the role of the early-life gut microbiome in the development of immune tolerance. She has served as principal investigator on numerous clinical trials evaluating emerging therapies for allergic diseases. She is a member of the Joint Task Force on Practice Parameters workgroup responsible for updating the Allergen Immunotherapy Practice Parameter, past chair of the American Academy of Allergy, Asthma, and Immunology's Immunotherapy, Allergen Standardization, and Allergy Diagnostics Committee, and a member of the American College of Allergy, Asthma, and Immunology's Immunotherapy Committee. She also serves on the editorial boards of The Journal of Allergy and Clinical Immunology: In Practice and Annals of Allergy, Asthma & Immunology.

Dr. Ponda earned her bachelor's degree from Cornell University and her medical degree from SUNY Downstate Medical Center. She completed her pediatrics residency and allergy and immunology fellowship at Schneider Children's Hospital within the North Shore—Long Island Jewish Health System.

Ronald Rabin, MD



Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Dr. Rabin joined the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) in 2001, and was appointed chief of the Laboratory of Immunobiochemistry (LIB) in 2008. Dr. Rabin supervises the reference reagent laboratory to ensure proper potency measurements of standardized allergen extracts and the evaluation of "chemistry, manufacturing and controls" (CMC) for allergenic products that are in clinical studies or under consideration for licensure. Dr. Rabin also leads a research laboratory that investigates the effect of allergens on innate immune responses to respiratory viral infections, and the application of proteomics towards characterization and standardization of allergen extracts.

Dr. Rabin received his medical degree at the University of South Florida College of Medicine. He completed his residency in pediatrics at the University of Kentucky and his fellowship in allergy and immunology at the National Institute of Allergy and Infectious Diseases (NIAID). In addition to his clinical experience, Dr. Rabin was a research fellow in laboratories at both Stanford University and NIAID.

Wayne Shreffler, MD, PhD



Harvard Medical School, Mass General Brigham

Dr. Shreffler is chief of pediatric allergy and immunology and director of the Food Allergy Center at Mass General Brigham (MGB), and an Investigator at the Center for Immunology and Inflammatory Disease as well as the Food Allergy Science Initiative. Since joining MGB in 2010, he has developed a highly integrated research and clinical program to better understand how adaptive immunity to dietary antigens is both naturally regulated and modulated by therapy in the context of food allergy.

Dr. Shreffler has authored more than 70 papers, maintained continuous research funding since 2007, and served on the editorial board of The Journal of Allergy and Clinical Immunology and as a reviewer for numerous journals and grant study sections/committees. He was elected a Fellow of the American Academy of Allergy, Asthma, and Immunology.

Dr. Shreffler earned his medical degree and PhD from New York University and his pediatrics training at the Albert Einstein College of Medicine. He completed his fellowship in allergy and immunology at the Mount Sinai School of Medicine.

Biographies of Speakers

Scott Sicherer, MD



Icahn School of Medicine at Mount Sinai

Dr. Sicherer is the Elliot and Roslyn Jaffe professor of allergy, immunology and pediatrics, director of the Jaffe Food Allergy Institute, and chief of the Serena and John Liew Division of Pediatric Allergy. His research interests, funded by the National Institute of Allergy and Infectious Diseases, FARE (Food Allergy Research & Education), and others, include numerous aspects of food allergy. He has held leadership roles in the Consortium for Food Allergy Research since its inception, has authored over 300 peer-reviewed publications, seven food allergy books for the lay public, and serves as Editor-in-Chief of the Encyclopedia of Food Allergy as well as Deputy Editor of the Journal of Allergy and Clinical Immunology: In Practice. He is recognized among the top 1% of researchers in this field by Clarivate.

Dr. Sicherer received his medical degree from Johns Hopkins. He completed pediatric residency and chief residency at Mount Sinai and an allergy and immunology fellowship at Johns Hopkins.

Kelly Stone, MD, PhD



Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Dr. Stone is a pediatrician and allergist/immunologist who serves as a supervisory physician and Associate Director for Therapeutic Review in the Division of Pulmonology, Allergy, and Critical Care, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). In this role, he supervises regulatory review of INDs and NDAs/BLAs for products related to allergic/immunologic diseases and asthma. He serves on the FDA Pediatric Review Committee and was the recipient of a CDER Excellence in Mentoring Award and two group recognition awards for his efforts in guidance, development, and review of products to treat COVID-19.

Prior to his role at the FDA, Dr. Stone served on the faculty at Children's Hospital, Boston and Children's National Medical Center, then spent 12 years at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) where he was Deputy Chief of the Laboratory of Allergic Diseases, Director of the NIH Clinical Center Allergy and Immunology Fellowship Program, and a senior clinician. At NIH, he was the recipient of the NIH Clinical Center Distinguished Clinical Teacher Award, the NIH Director's Ruth Kirschstein Mentoring Award, an NIH Director's Award for scientific accomplishment, as well as several NIAID Director's Awards for clinical research and administrative accomplishments. He has served on the Board of Directors of the American Academy of Allergy, Asthma, and Immunology and as a member of the FDA Pulmonary and Allergy Drugs Advisory Committee. He is the current chair of the Accreditation Council for Graduate Medical Education (ACGME) Allergy and Immunology Review Committee and chairs the ACGME Reshaping the Future of Allergy and Immunology working group.

Dr. Stone earned his bachelor's degree from Johns Hopkins University and MD as well as PhD in molecular and cell biology from the University of Maryland School of Medicine. He completed pediatric residency at Children's National Medical Center and fellowship training in Immunology at Children's Hospital, Boston.

Stephen Tilles, MD
Clinical Development Day Co-chair



FARE (Food Allergy Research & Education) and University of Washington

Dr. Tilles is a board-certified allergist, clinical professor at the University of Washington, and founder of Advanced Allergy Insights LLC. He is FARE's Research and Strategic Innovation Advisor. His previous roles include a consultant for Stallergenes Greer, medical director at Aimmune Therapeutics, 23 years in clinical practice, and 18 years as executive director of ASTHMA Inc Clinical Research Center where he was principal investigator on more than 140 clinical trials. He is a former American Board of Allergy and Immunology member and past president of the American College of Allergy, Asthma, and Immunology.

Dr. Tilles earned his medical degree from the University of California, San Diego School of Medicine, completed his residency in internal medicine at Oregon Health & Science University, and pursued fellowship training in Allergy and Immunology at the University of Colorado School of Medicine and National Jewish Health.

Alkis Togias, MD



National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Dr. Togias is acting director of the Division of Allergy, Immunology, and Transplantation (DAIT), chief of the Allergy, Asthma, and Airway Biology Branch at DAIT, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He supervises the stewardship of all NIAID-funded grants and programs, as well as the scientific research initiatives in allergic diseases, asthma, and inflammatory upper airway conditions. This includes the NIAID-funded clinical networks Childhood Asthma in Urban Settings (CAUSE), Consortium for Food Allergy Research (CoFAR), Atopic Dermatitis Research Network (ADRN), Asthma and Allergic Diseases Cooperative Research Centers (AADCRC), and the allergy projects of the Immune Tolerance Network (ITN), as well as investigator-initiated clinical trials and investigator-initiated research project grants. Dr. Togias also co-directs the NIAID-funded Human Immunology Project Consortium (HIPC) and is a project scientist in the Airways Workgroup of the NIH-funded Environmental Influences on Child Health Outcomes (ECHO) initiative.

Dr. Togias earned his medical degree at the National and Kapodistrian University of Athens, Greece, and received his postdoctoral research and clinical training in medicine and then in allergy and clinical immunology at The Johns Hopkins Hospital and Johns Hopkins University. He was on faculty at Johns Hopkins University from 1989 to 2006, when he joined the NIH.

Biographies of Speakers

Anubha Tripathi, MD



Center for Biologics Evaluation and Research, U.S. Food and Drug Administration

Dr. Tripathi conducts clinical review for the FDA's Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, and Division of Clinical and Toxicology Review as a physician subspecialized in the field of allergy and clinical immunology. While her current role is primarily focused on the comprehensive evaluation of clinical development programs, including evaluation of safety and effectiveness data for investigational allergenic, vaccine, and related biological therapeutic products, she is also extensively involved in other aspects of this role. These include authoring publications in subspecialty medical journals and books including JACI and the Encyclopedia of Food Allergy; presenting to and discussing relevant regulatory information with various external subspecialty organizations including AAAAI, Paul Ehrlich Institute, APMA, and FARE; and aiding in the development of policy and of FDA workshops on various topics of importance to the field of allergy and clinical immunology.

After completing her residency training in internal medicine at Tufts Medical Center, Dr. Tripathi served as an attending physician in both hospital and medical practice settings. She completed her clinical and research fellowship in allergy and clinical immunology in the University of Virginia Health System's Division of Allergy and Clinical Immunology, where she also served on faculty as an assistant professor in Medicine. During her tenure, she served as a principal investigator, co-investigator, and sub-investigator in clinical trials and research studies investigating various food allergies and eosinophilic esophagitis. She also authored several publications in these areas in various books and medical journals including JACI and JACI: In Practice and presented her research findings in these areas at the annual meetings of numerous medical subspecialty organizations including those of the American Academy of Asthma, Allergy and Immunology, the American College of Asthma, Allergy and Immunology, the European Academy of Allergy & Clinical Immunology, and Digestive Disease Week.



Brian Vickery, MD



Emory University School of Medicine

Dr. Vickery is professor of Pediatrics, Marcus professor of Pediatric Immunology, and chief of the Division of Allergy and Immunology at Emory University School of Medicine and Children's Healthcare of Atlanta. He also serves as vice chair for Clinical Research in the Department of Pediatrics and is the founding director of the Food Allergy Center at Emory and Children's. A pediatric allergist-immunologist and physician-scientist, Dr. Vickery focuses on understanding the mechanisms underlying food allergy and anaphylaxis and developing innovative therapies to improve patient outcomes.

Dr. Vickery has been a leader in food allergy therapeutic development, with research spanning preclinical investigation, translational studies, and phase 3 clinical trials. His work has helped establish the potential for sustained unresponsiveness following peanut oral immunotherapy (OIT) and demonstrated that early intervention in preschool-aged children can improve treatment outcomes. He previously held faculty appointments at Duke University and the University of North Carolina at Chapel Hill, where he directed the UNC Food Allergy Initiative. He also served as senior medical director at Aimmune Therapeutics, leading a pivotal international phase 3 clinical trial of peanut OIT. His contributions have helped advance evidence-based approaches to food allergy treatment and informed national clinical practice guidelines.

Dr. Vickery completed his undergraduate studies at the University of Georgia and earned his medical degree from the Medical College of Georgia. He completed his pediatrics residency and chief residency at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, followed by fellowship training in allergy and clinical immunology at Yale University School of Medicine.

Yamini Vikas Virkud, MD, MA, MPH
Clinical Development Day Co-chair



University of North Carolina at Chapel Hill

Dr. Virkud is associate professor of pediatrics at the University of North Carolina at Chapel Hill (UNC) School of Medicine, director of Bioinformatics for the UNC Food Allergy Initiative, and adjunct faculty at Massachusetts General Hospital (MGH). She is a pediatric allergist-immunologist and physician-scientist whose research focuses on characterizing food allergy phenotypes, understanding the mechanisms of investigational therapies, and identifying predictors of treatment response to advance precision approaches to food allergy management.

From 2014 to 2021, Dr. Virkud held faculty appointments at MGH and Harvard Medical School, where she served as director of the Biostatistics and Data Management Core of the MGH Food Allergy Center. She joined the UNC Food Allergy Initiative in 2021. Her research integrates clinical investigation, epidemiology, biostatistics, and molecular profiling to better understand food allergy heterogeneity and immune tolerance.

Dr. Virkud earned her medical degree and a master's degree in biology and biomedical sciences from Washington University in St. Louis. She completed her pediatrics residency at St. Louis Children's Hospital and her allergy and immunology fellowship at Duke University, where she investigated the safety of peanut oral immunotherapy under the mentorship of Dr. Wesley Burks. She also completed a clinical research fellowship at the Duke Clinical Research Institute and earned a Master of Public Health.

Biographies of Speakers

Julie Wang, MD



Icahn School of Medicine at Mount Sinai

Dr. Wang is professor of Pediatrics in the Serena and John Liew Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai (ISMMS). Dr. Wang's research focuses on clinical trials developing new treatments for food allergy as well as studies aimed at better understanding how patients and their families manage food allergy and anaphylaxis in schools and other community settings.

As a member of the Joint Task Force on Practice Parameters and immediate-past chair of the Executive Committee of the Section on Allergy and Immunology of the American Academy of Pediatrics, Dr. Wang has co-authored pediatric and allergy guidelines on food allergy and anaphylaxis. She is also a member of the board of directors of the American Board of Allergy and Immunology and past chair of the American Academy of Allergy, Asthma, and Immunology Annual Meeting Programming Committee. She has published over 170 articles in scientific journals and has authored over 20 book chapters in major pediatric and allergy textbooks. Dr. Wang is on the editorial board for the Journal of Allergy and Clinical Immunology and Journal of Allergy and Clinical Immunology: In Practice. She is co-program director for the Mount Sinai Allergy and Immunology Fellowship Training Program.

Dr. Wang earned her medical degree from Weill Cornell Medical College, completed her pediatrics residency at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and pursued fellowship training in Allergy and Immunology at Mount Sinai Hospital.

Sherry Zhou, MD, MSc



ALK-Abelló

Dr. Zhou is a medical director at ALK-Abelló, a global biopharmaceutical company specializing in allergy immunotherapy. A physician with experience spanning clinical practice, regulatory science, and pharmaceutical development, Dr. Zhou brings a multidisciplinary perspective to the development and evaluation of therapies for allergic diseases.

Prior to joining ALK-Abelló, Dr. Zhou served as a clinical reviewer in the Division of Dermatology and Dentistry within the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). Her experience at the FDA provided expertise in the clinical evaluation of investigational therapies, regulatory review, and the assessment of evidence supporting drug safety and efficacy. Her combined experience in government and industry informs her approach to therapeutic development, clinical evidence generation, and regulatory considerations affecting the availability of new treatments.

Dr. Zhou earned her medical degree from New York University School of Medicine and completed postgraduate clinical training at the University of Michigan. She also holds a Master of Science degree in clinical investigation from New York University.

Thank You to Our Generous Sponsors

Genentech
A Member of the Roche Group

dbv technologies

ALK

DELTA

FARE

FARE (Food Allergy Research & Education) is the leading nonprofit organization working on behalf of more than 33 million people in the U.S. living with food allergy, a serious disease of the immune system that can cause anaphylaxis, a potentially life-threatening allergic reaction. FARE works to advance evidence-based prevention as a public health priority, expand options for the diagnosis, management, and treatment of food allergy, and accelerate research toward a cure. Through research, education, advocacy, and collaboration, FARE is driving progress to improve the health and quality of life for people managing food allergy.

To learn more, visit **FoodAllergy.org.**

Follow FARE on social media!